Advances in Clinical Applications of Kisspeptin-GnRH Pathway in Female Reproduction

Overview

Journal Reprod Biol Endocrinol

Publisher Biomed Central

Specialties Endocrinology
Reproductive Medicine

Date 2022 May 23

PMID 35606759

Authors

Kai-Lun Hu

Zimiao Chen

Xiaoxue Li

Enci Cai

Haiyan Yang

Yi Chen

Congying Wang

Liping Ju

Wenhai Deng

Liangshan Mu

Affiliations

Soon will be listed here.

Abstract

Background: Kisspeptin is the leading upstream regulator of pulsatile and surge Gonadotrophin-Releasing Hormone secretion (GnRH) in the hypothalamus, which acts as the key governor of the hypothalamic-pituitary-ovary axis.

Main Text: Exogenous kisspeptin or its receptor agonist can stimulate GnRH release and subsequent physiological gonadotropin secretion in humans. Based on the role of kisspeptin in the hypothalamus, a broad application of kisspeptin and its receptor agonist has been recently uncovered in humans, including central control of ovulation, oocyte maturation (particularly in women at a high risk of ovarian hyperstimulation syndrome), test for GnRH neuronal function, and gatekeepers of puberty onset. In addition, the kisspeptin analogs, such as TAK-448, showed promising agonistic activity in healthy women as well as in women with hypothalamic amenorrhoea or polycystic ovary syndrome.

Conclusion: More clinical trials should focus on the therapeutic effect of kisspeptin, its receptor agonist and antagonist in women with reproductive disorders, such as hypothalamic amenorrhoea, polycystic ovary syndrome, and endometriosis.

Citing Articles

History of the Development of Knowledge about the Neuroendocrine Control of Ovulation-Recent Knowledge on the Molecular Background.

Szabo F, Koves K, Gal L Int J Mol Sci. 2024; 25(12).

PMID: 38928237 PMC: 11203711. DOI: 10.3390/ijms25126531.

Urinary gonadotropin assay on 24-h collections as a tool to detect early central puberty onset in girls: determination of predictive thresholds.

Janot C, Perrin P, Raverot V, Bretones P, Ecochard R, Malburet-Testori S Hum Reprod. 2024; 39(5):1003-1012.

PMID: 38514451 PMC: 11063551. DOI: 10.1093/humrep/deae055.

Arcuate Nucleus of the Hypothalamus: Anatomy, Physiology, and Diseases.

Song J, Choi S Exp Neurobiol. 2024; 32(6):371-386.

PMID: 38196133 PMC: 10789173. DOI: 10.5607/en23040.

Neuroendocrine disturbances in women with functional hypothalamic amenorrhea: an update and future directions.

Meczekalski B, Niwczyk O, Battipaglia C, Troia L, Kostrzak A, Bala G Endocrine. 2023; 84(3):769-785.

PMID: 38062345 PMC: 11208264. DOI: 10.1007/s12020-023-03619-w.

Signaling pathways and targeted therapeutic strategies for polycystic ovary syndrome.

Wang K, Li Y Front Endocrinol (Lausanne). 2023; 14:1191759.

PMID: 37929034 PMC: 10622806. DOI: 10.3389/fendo.2023.1191759.

References

de Vries L, Shtaif B, Phillip M, Gat-Yablonski G . Kisspeptin serum levels in girls with central precocious puberty. Clin Endocrinol (Oxf). 2009; 71(4):524-8. DOI: 10.1111/j.1365-2265.2009.03575.x. View

Okamura H, Tsukamura H, Ohkura S, Uenoyama Y, Wakabayashi Y, Maeda K . Kisspeptin and GnRH pulse generation. Adv Exp Med Biol. 2013; 784:297-323. DOI: 10.1007/978-1-4614-6199-9_14. View

Raivio T, Falardeau J, Dwyer A, Quinton R, Hayes F, Hughes V . Reversal of idiopathic hypogonadotropic hypogonadism. N Engl J Med. 2007; 357(9):863-73. DOI: 10.1056/NEJMoa066494. View

Seminara S, Messager S, Chatzidaki E, Thresher R, Acierno Jr J, Shagoury J . The GPR54 gene as a regulator of puberty. N Engl J Med. 2003; 349(17):1614-27. DOI: 10.1056/NEJMoa035322. View

Millar R, Newton C . Current and future applications of GnRH, kisspeptin and neurokinin B analogues. Nat Rev Endocrinol. 2013; 9(8):451-66. DOI: 10.1038/nrendo.2013.120. View

Ullah H, Nabi G, Zubair H, Ullah R, Shahab M . Age-dependent changes in the reproductive axis responsiveness to kisspeptin-10 administration in healthy men. Andrologia. 2018; 51(4):e13219. DOI: 10.1111/and.13219. View

Bianco S, Kaiser U . The genetic and molecular basis of idiopathic hypogonadotropic hypogonadism. Nat Rev Endocrinol. 2009; 5(10):569-76. PMC: 2864719. DOI: 10.1038/nrendo.2009.177. View

Scott G, Ahmad I, Howard K, MacLean D, Oliva C, Warrington S . Double-blind, randomized, placebo-controlled study of safety, tolerability, pharmacokinetics and pharmacodynamics of TAK-683, an investigational metastin analogue in healthy men. Br J Clin Pharmacol. 2012; 75(2):381-91. PMC: 3579253. DOI: 10.1111/j.1365-2125.2012.04385.x. View

Albers-Wolthers C, de Gier J, Walen M, van Kooten P, Lambalk C, Leegwater P . In vitro and in vivo effects of kisspeptin antagonists p234, p271, p354, and p356 on GPR54 activation. PLoS One. 2017; 12(6):e0179156. PMC: 5484485. DOI: 10.1371/journal.pone.0179156. View

10.

Ramaswamy S, Seminara S, Ali B, Ciofi P, Amin N, Plant T . Neurokinin B stimulates GnRH release in the male monkey (Macaca mulatta) and is colocalized with kisspeptin in the arcuate nucleus. Endocrinology. 2010; 151(9):4494-503. PMC: 2940495. DOI: 10.1210/en.2010-0223. View

11.

Jayasena C, Nijher G, Comninos A, Abbara A, Januszewki A, Vaal M . The effects of kisspeptin-10 on reproductive hormone release show sexual dimorphism in humans. J Clin Endocrinol Metab. 2011; 96(12):E1963-72. PMC: 3232613. DOI: 10.1210/jc.2011-1408. View

12.

Garcia-Galiano D, Pinilla L, Tena-Sempere M . Sex steroids and the control of the Kiss1 system: developmental roles and major regulatory actions. J Neuroendocrinol. 2011; 24(1):22-33. DOI: 10.1111/j.1365-2826.2011.02230.x. View

13.

Jayasena C, Nijher G, Chaudhri O, Murphy K, Ranger A, Lim A . Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis. J Clin Endocrinol Metab. 2009; 94(11):4315-23. DOI: 10.1210/jc.2009-0406. View

14.

Tomita K, Narumi T, Niida A, Oishi S, Ohno H, Fujii N . Fmoc-based solid-phase synthesis of GPR54-agonistic pentapeptide derivatives containing alkene- and fluoroalkene-dipeptide isosteres. Biopolymers. 2007; 88(2):272-8. DOI: 10.1002/bip.20676. View

15.

Doebelin C, Bertin I, Schneider S, Schmitt M, Bourguignon J, Ancel C . Development of Dipeptidic hGPR54 Agonists. ChemMedChem. 2016; 11(19):2147-2154. DOI: 10.1002/cmdc.201600331. View

16.

Carel J, Leger J . Clinical practice. Precocious puberty. N Engl J Med. 2008; 358(22):2366-77. DOI: 10.1056/NEJMcp0800459. View

17.

dAnglemont de Tassigny X, Jayasena C, Murphy K, Dhillo W, Colledge W . Mechanistic insights into the more potent effect of KP-54 compared to KP-10 in vivo. PLoS One. 2017; 12(5):e0176821. PMC: 5413024. DOI: 10.1371/journal.pone.0176821. View

18.

Berga S, Girton L . The psychoneuroendocrinology of functional hypothalamic amenorrhea. Psychiatr Clin North Am. 1989; 12(1):105-16. View

19.

Nishizawa N, Takatsu Y, Kumano S, Kiba A, Ban J, Tsutsumi S . Design and Synthesis of an Investigational Nonapeptide KISS1 Receptor (KISS1R) Agonist, Ac-d-Tyr-Hydroxyproline (Hyp)-Asn-Thr-Phe-azaGly-Leu-Arg(Me)-Trp-NH (TAK-448), with Highly Potent Testosterone-Suppressive Activity and Excellent Water Solubility. J Med Chem. 2016; 59(19):8804-8811. DOI: 10.1021/acs.jmedchem.6b00379. View

20.

Spaziani M, Tarantino C, Tahani N, Gianfrilli D, Sbardella E, Lenzi A . Hypothalamo-Pituitary axis and puberty. Mol Cell Endocrinol. 2020; 520:111094. DOI: 10.1016/j.mce.2020.111094. View